Back to Awarded Treatment Trials


Awarded Trial: 01-074

Grant ID

01-074

Illness

Schizophrenia

Primary Drug/Intervention

Risperidone Added to Clozapine

Primary Dosage

2-6mg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Anil

Sample Size

30

Duration of Study Period for Each Subject

6 weeks

Outcome Measurements

PANSS, CGI-S, CDS, GAF, QLS

Results

30 patients with schizophrenia who had partial response to clozapine received either placebo or risperidone augmentation in a six week double-blind, randomized, design. Both groups improved on a variety of measures of psychopathology but there was significantly greater improvement in placebo treated patients on the PANSS positive subscale. In evaluating the results it may be noteworthy that duration of illness, clozapine dose and number of previous hospitaizations were higher in the group that received risperidone.

Publication

Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005 Jan;66(1):63-72. Kivircik Akdede BB, Anil Yagcioglu AE, Alptekin K et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry. 2006 Dec;67(12):1912-9.

Link

http://www.ncbi.nlm.nih.gov/pubmed/15669890; http://www.ncbi.nlm.nih.gov/pubmed/17194269

PI Name

Elif Anil

Degree

MD

Center

Department of Psychiatry

Institution

Hacettepe University, Faculty of Medicine

Address

Sihhiye

City or Town

Ankara

State or Province

N/A

Zip or Postal Code

6100

Country

Turkey

Email Address

eanil@hacettepe.edu.tr